Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clinical Pathway Clear all
Terminated Phase 1 Interventional

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955
View directory record Official record
Conditions
Solid Tumors, Ovarian Cancer, Endometrial Cancer
Interventions
ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02574078
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 12, 2026, 10:35 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital

NCT07606287
View directory record Official record
Conditions
Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Head and Neck Neoplasm, Malignant Nervous System Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm, Central Nervous System Neoplasm, Endocrine Gland Neoplasms
Interventions
Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

Podocan and Wnt Pathway in Left Ventricular Remodeling of Aortic Stenosis

NCT02624934
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 1Phase 2 Interventional

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

NCT01543659
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr-DFO-huJ591
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

NCT02982954
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
61
States / cities
Muscle Shoals, Alabama • Anchorage, Alaska • Chandler, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NAFLD Clinical Care Pathway

NCT06671886
View directory record Official record
Conditions
NAFLD, MASLD
Interventions
E-trigger
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Not applicable Interventional

Fall Risk Identification and Management for Older Veterans

NCT06573983
View directory record Official record
Conditions
Fall Risk
Interventions
Strengthening (Physical Therapy, Gerofit), Medication Reconciliation (Clinical Pharmacology), Home Safety Modification (Occupational Therapy)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Phase 4 Interventional Results available

Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

NCT02686749
View directory record Official record
Conditions
Congestive Heart Failure, Left Ventricular Failure, Atrial Fibrillation
Interventions
Catheter Ablation, FDA approved anti arrhythmic drug
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Hartford, Connecticut • Akron, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction

NCT05223322
View directory record Official record
Conditions
Breast Cancer
Interventions
Taking Charge during Treatment (TCT) Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Enrolling by invitation Not applicable Interventional

Automated Clinical Pathway for Inflammatory Bowel Disease Care

NCT07167836
View directory record Official record
Conditions
Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)
Interventions
Electronic medical record-based care pathway
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

NCT06011187
View directory record Official record
Conditions
Decision Support System, Outcome
Interventions
Routine care, AFM
Procedure · Device
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Other
Eligibility
18 Years and older
Enrollment
2,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

NCT04486833
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
Biological · Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer

NCT00897832
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Not applicable Interventional

Study of Automated Care Pathway for Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03028805
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Diseases, Obstructive
Interventions
Automatic inclusion of COPD orders in admission orders, Dynamic, end-user order set design
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 12, 2026, 10:35 AM EDT
Completed No phase listed Observational

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

NCT07477756
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated Not applicable Interventional

Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.

NCT02470728
View directory record Official record
Conditions
Pain, Acute Pain, Postoperative Pain
Interventions
New Clinical Pathway
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Orange, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Terminated No phase listed Observational

Keloid Tissue Bank

NCT01425437
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
Tirgan, Michael H., M.D.
Individual
Eligibility
13 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional

A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors

NCT04594473
View directory record Official record
Conditions
Breast Cancer
Interventions
Comprehensive Oncology Rehabilitation and Exercise (CORE) Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 12, 2026, 10:35 AM EDT
Recruiting Phase 1 Interventional

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

NCT05111561
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Aiming to Improve Readmissions Through InteGrated Hospital Transitions

NCT02763202
View directory record Official record
Conditions
Hospital Readmission
Interventions
CHS Transition Services
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial

NCT04872413
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Follow-Up
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 12, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT02596035
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 12, 2026, 10:35 AM EDT